Calcitonin therapy in osteoporosis

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Osteoporosis is a prevalent metabolic bone disease characterized by reduced bone strength and increased fracture risk, particularly in postmenopausal women.
• Calcitonin, a peptide hormone, inhibits osteoclast function and has been used to treat osteoporosis, with intranasal formulations offering improved tolerability over parenteral injections.
• Emerging research explores enhanced calcitonin delivery methods and novel receptor activators to improve bioavailability and efficacy.

Purpose of the Study:

• To evaluate the efficacy of salmon calcitonin nasal spray in preventing osteoporotic fractures.
• To assess the impact of different calcitonin dosages on bone density and fracture risk.
• To investigate the potential of calcitonin in managing bone pain associated with vertebral fractures and its role in specific osteoporosis types.

Main Methods:

• The Prevent Recurrence of Osteoporotic Fractures (PROOF) study, a 5-year double-blind, randomized, placebo-controlled trial, evaluated salmon calcitonin nasal spray.
• Participants received dosages of 100, 200, or 400 IU/day.
• Bone density changes and fracture incidence (vertebral and nonvertebral) were primary endpoints, alongside assessments of bone pain.

Main Results:

• Salmon calcitonin nasal spray at 200 IU/day reduced the risk of vertebral osteoporotic fractures by 33% (RR = 0.67; p = 0.03).
• Dosages of 100 and 400 IU/day did not significantly reduce vertebral fracture risk, and effects on nonvertebral fractures were not significant (RR = 0.80; p = 0.16).
• Calcitonin demonstrated efficacy in diminishing bone pain associated with osteoporotic vertebral fractures and shows promise for idiopathic osteoporosis in men.

Conclusions:

• Intranasal salmon calcitonin at 200 IU/day is effective in reducing vertebral fracture risk in osteoporosis.
• Calcitonin may offer clinical utility in managing bone pain from vertebral crush fractures and treating idiopathic osteoporosis in men.
• Its role in corticosteroid-induced osteoporosis remains controversial, positioning it as a second-line treatment option.